Status
Ongoing
Project acroniem
NTRK
Introduction
Larotrectinib (Vitrakvi®) and Entrectinib (Rozlytrek®) are drugs developed for the treatment of locally advanced or metastatic solid tumours with neurotrophic tyrosine receptor kinase (NTRK) gene fusion. These tumours are not (or no longer) eligible for conventional cancer treatment by surgery, chemotherapy or radiotherapy.
Objective
For a specific patient group, namely patients who (1) have been diagnosed with an NTRK gene fusion-related tumour without a known acquired resistance mutation, (2) have a tumour that is locally advanced or metastatic and/or where surgical resection is likely to result in severe morbidity, and (3) have received inadequate alternative treatments, tumour and outcome data are registered in addition to cancer data.
This data registration is a requirement for drug reimbursement by the Rijksinstituut voor Ziekte- en Invaliditeitsverzekering (RIZIV) (National Institute for Health and Disability Insurance). Reimbursement can be approved on the basis of an electronic application via the ehealth platform. The project database contains data of patients treated with Larotrectinib since 1 April 2021 and with Entrectinib since 1 October 2021.
Financial support and partners
This registration project is run in collaboration with the various health insurance organisations and the RIZIV.
Contact
For more information about this registration project, contact ntrkinhibitor@kankerregister.org.
Larotrectinib (Vitrakvi®) and Entrectinib (Rozlytrek®) are drugs developed for the treatment of locally advanced or metastatic solid tumours with neurotrophic tyrosine receptor kinase (NTRK) gene fusion. These tumours are not (or no longer) eligible for conventional cancer treatment by surgery, chemotherapy or radiotherapy.
Objective
For a specific patient group, namely patients who (1) have been diagnosed with an NTRK gene fusion-related tumour without a known acquired resistance mutation, (2) have a tumour that is locally advanced or metastatic and/or where surgical resection is likely to result in severe morbidity, and (3) have received inadequate alternative treatments, tumour and outcome data are registered in addition to cancer data.
This data registration is a requirement for drug reimbursement by the Rijksinstituut voor Ziekte- en Invaliditeitsverzekering (RIZIV) (National Institute for Health and Disability Insurance). Reimbursement can be approved on the basis of an electronic application via the ehealth platform. The project database contains data of patients treated with Larotrectinib since 1 April 2021 and with Entrectinib since 1 October 2021.
Financial support and partners
This registration project is run in collaboration with the various health insurance organisations and the RIZIV.
Contact
For more information about this registration project, contact ntrkinhibitor@kankerregister.org.
